Thursday, March 19, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Almonty Industries Approaches All-Time High on Operational Milestones

Dieter Jaworski by Dieter Jaworski
February 1, 2026
in Analysis, Commodities, Emerging Markets, Industrial
0
Almonty Stock
0
SHARES
24
VIEWS
Share on FacebookShare on Twitter

Shares of Almonty Industries are trading near record levels, driven not by short-term headlines but by significant operational progress. The company’s flagship Sangdong tungsten mine in South Korea entered commercial production in December 2025, shifting investor focus squarely onto production targets and supply chain dynamics. This development is particularly timely, given the tungsten market has tightened considerably.

The critical question for the industry is whether Sangdong can become a cornerstone for non-Chinese supply. The answer hinges on the mine’s ramp-up to full capacity.

Strategic Shift as Production Commences

The transition from construction to active production in late 2025 marks a fundamental change for Almonty. Company leadership has stated that at full capacity, Sangdong could supply approximately 40% of the global non-Chinese demand within its market segment.

This strategic position is bolstered by regulatory tailwinds. A ban on Chinese tungsten imports for U.S. defense applications is scheduled for 2027, increasing pressure on Western supply chains to secure alternative sources. The mine’s launch coincides with a favorable pricing environment; tungsten prices surged by over 160% in 2025, according to market data, providing a strong backdrop for new production.

Key Data Points:
* Sangdong Status: Commercial production began December 2025
* Tungsten Price: Increased more than 160% in 2025
* Recent Share Price (Frankfurt Close): €9.75
* Market Capitalization: Approximately €2.66 billion

Should investors sell immediately? Or is it worth buying Almonty?

Capital Management and Insider Activity

Recent corporate filings show activity on two fronts. In January, director Thomas Joerg Gutschlag sold 89,630 shares valued at around CAD 1.2 million, reducing his holding by roughly 7.5%.

Separately, the company issued a “Cleansing Statement” yesterday regarding the allotment of 370,303 new common shares. This move is part of ongoing capital management as Almonty scales its operations across multiple jurisdictions.

Forward Outlook: North American Expansion and Upcoming Report

While Sangdong ramps up, Almonty is advancing its North American expansion. The company’s Gantung Browns Lake project in Montana is currently targeted to begin production in the second half of 2026.

In the near term, market attention will center on how swiftly Sangdong’s output translates into revenue. Investors await the next financial report, currently expected on March 27, 2026, for the first concrete figures from the new producing asset.

Ad

Almonty Stock: Buy or Sell?! New Almonty Analysis from March 19 delivers the answer:

The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 19.

Almonty: Buy or sell? Read more here...

Tags: Almonty
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Taxus Cardium Stock
Analysis

Silence Persists for Gene Biotherapeutics Investors

March 19, 2026
Earlyworks Stock
AI & Quantum Computing

Scaling Operations: The Central Challenge for Earlyworks Stock

March 19, 2026
Lumentum Stock
AI & Quantum Computing

Lumentum’s Ambitious Target: A $2 Billion Quarterly Revenue Run Rate

March 19, 2026
Next Post
Alphabet Stock

Alphabet's Valuation Boosted by Autonomous Driving Ambitions

Diginex Stock

Diginex Pivots to Sustainability Tech with New Leadership

Rocket Lab USA Stock

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

Recommended

Agilent Stock

FDA Clearance Positions Agilent for Potential Turnaround

7 months ago
Cooper-Standard Stock

Cooper-Standard Shares Maintain Upward Momentum

7 months ago
Finances

Nuvei Corporation Reports Record Revenues for Q4 and Fiscal Year 2024

2 years ago
Keurig Dr Pepper Inc Stock

Keurig Dr Pepper Faces Investor Skepticism Following Major Acquisition Plan

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Legal Headwinds Challenge AbbVie Amid Strong Pipeline Growth

New Fortress Energy Seeks Stability Through Major Debt-to-Equity Conversion

Sysco’s Steady Course Amid Leadership Transition

Harmony Gold Announces Doubled Dividend Amid Strategic Pivot

Precision Biosciences Charts Definitive Clinical Pathway

Institutional Investors Recalibrate Positions in AI Infrastructure Specialist Astera Labs

Trending

Taxus Cardium Stock
Analysis

Silence Persists for Gene Biotherapeutics Investors

by Kennethcix
March 19, 2026
0

For shareholders of Gene Biotherapeutics, the wait for substantive news continues. The company, formerly known as Taxus...

Earlyworks Stock

Scaling Operations: The Central Challenge for Earlyworks Stock

March 19, 2026
Lumentum Stock

Lumentum’s Ambitious Target: A $2 Billion Quarterly Revenue Run Rate

March 19, 2026
AbbVie Stock

Legal Headwinds Challenge AbbVie Amid Strong Pipeline Growth

March 19, 2026
New Fortress Energy Stock

New Fortress Energy Seeks Stability Through Major Debt-to-Equity Conversion

March 19, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Silence Persists for Gene Biotherapeutics Investors
  • Scaling Operations: The Central Challenge for Earlyworks Stock
  • Lumentum’s Ambitious Target: A $2 Billion Quarterly Revenue Run Rate

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com